Nkx3.1 controls the DNA repair response in the mouse prostate

Prostate

Volumn 76, Issue 4, 2016, Pages 402-408

  Zhang, Hailan ^a   Zheng, Tian ^a   Chua, Chee Wai ^a   Shen, Michael ^a   Gelmann, Edward P ^a  

^a Department of Medicine   (United States)

Author keywords

DNA repair; haploinsufficiency; NKX3.1; histone 2AX

Indexed keywords

ETOPOSIDE; HISTONE H2AX; MITOMYCIN; DNA; HOMEODOMAIN PROTEIN; NKX3-1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; GAMMA IRRADIATION; HAPLOINSUFFICIENCY; MALE; MOUSE; NKX3.1 GENE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; TUMOR SUPPRESSOR GENE; ANIMAL; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; GAMMA RADIATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MUTANT MOUSE STRAIN; PHYSIOLOGY; RADIATION RESPONSE;

ANIMALS; DNA; DNA DAMAGE; DNA REPAIR; ETOPOSIDE; GAMMA RAYS; HOMEODOMAIN PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MITOMYCIN; PROSTATE; TRANSCRIPTION FACTORS;

EID: 84955752838     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23131     Document Type: Article

References (27)

1. Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, Cheng L,. Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched foci of prostate carcinoma. Cancer 1998; 83 (9): 1995-2002.
2. Effert P, Neubauer A, Walther PJ, Liu ET,. Alterations of the p53 gene are associated with the progression of a human prostate carcinoma. J Urol 1992; 147: 789-793.
3. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM,. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009; 326 (5957): 1230.
4. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S,. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010; 42 (8): 668-675.
5. Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jager N, Gu L, Bogatyrova O, Stutz AM, Claus R, Eils J, Eils R, Gerhauser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Falth M, Gade S, Schmidt M, Amschler N, Hass T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von KC, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sultmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm T,. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013; 23 (2): 159-170.
6. Nelson WG, De Marzo AM, Isaacs WB,. Prostate cancer. N Engl J Med 2003; 349 (4): 366-381.
7. Bowen C, Gelmann EP,. NKX3.1 activates cellular response to DNA damage. Cancer Res 2010; 70 (8): 3089-3097.
8. Puc J, Kozbial P, Li W, Tan Y, Liu Z, Suter T, Ohgi KA, Zhang J, Aggarwal AK, Rosenfeld MG,. Ligand-dependent enhancer activation regulated by topoisomerase-I activity. Cell 2015; 160 (3): 367-380.
9. Bowen C, Ju JH, Lee JH, Paull TT, Gelmann EP,. Functional activation of ATM by the prostate cancer suppressor NKX3.1. Cell Rep 2013; 4 (3): 516-529.
10. Jaamaa S, Af Hallstrom TM, Sankila A, Rantanen V, Koistinen H, Stenman UH, Zhang Z, Yang Z, De Marzo AM, Taari K, Ruutu M, Andersson LC, Laiho M,. DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue. Cancer Res 2010; 70 (21): 8630-8641.
11. Long BH, Musial ST, Brattain MG,. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 1985; 45 (7): 3106-3112.
12. Tewey KM, Chen GL, Nelson EM, Liu LF,. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259 (14): 9182-9187.
13. Isaacs JT,. Antagonistic effect of androgen on prostatic cell death. Prostate 1984; 5: 545-545.
14. Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, Chiariotti L, Malorni A, Abbondanza C, Avvedimento EV,. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science 2008; 319 (5860): 202-206.
15. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM,. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10 (2): 177-188.
16. Bowen C, Zheng T, Gelmann EP,. NKX3.1 suppresses TMPRSS2-ERG gene rearrangement and mediates repair of androgen receptor-induced DNA damage. Cancer Res 2015.
17. Bowen C, Zheng T, Gelmann EP,. NKX3.1 suppresses TMPRSS2-ERG gene rearrangement and mediates repair of androgen receptor-induced DNA damage. Cancer Res 2015; 75 (13): 2686-2698.
18. Bowen C, Stuart A, Ju JH, Tuan J, Blonder J, Conrads TP, Veenstra TD, Gelmann EP,. NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity. Cancer Res 2007; 67 (2): 455-464.
19. Erbaykent-Tepedelen B, Karamil S, Gonen-Korkmaz C, Korkmaz KS,. DNA damage response (DDR) via NKX3.1 expression in prostate cells. J Steroid Biochem Mol Biol 2014; 141: 26-36.
20. Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, Jenkins RB, Bieberich CJ, De Marzo AM,. Decreased NKX3. 1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: Association with gleason score and chromosome 8p deletion. Cancer Res 2006; 66 (22): 10683-10690.
21. Khalili M, Mutton LN, Gurel B, Hicks JL, De Marzo AM, Bieberich CJ,. Loss of Nkx3.1 expression in bacterial prostatitis: A potential link between inflammation and neoplasia. Am J Pathol 2010; 176 (5): 2259-2268.
22. Markowski MC, Bowen C, Gelmann EP,. Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1. Cancer Res 2008; 68 (17): 6896-6901.
23. Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ,. Prostatitis as a risk factor for prostate cancer. Epidemiology 2004; 15 (1): 93-99.
24. Asatiani E, Huang WX, Wang A, Rodriguez OE, Cavalli LR, Haddad BR, Gelmann EP,. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res 2005; 65 (4): 1164-1173.
25. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR,. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007; 67 (18): 8504-8510.
26. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL,. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18 (1): 11-22.
27. Swalwell JI, Vocke CD, Yang Y, Walker JR, Grouse L, Myers SH, Gillespie JW, Bostwick DG, Duray PH, Linehan WM, Emmert-Buck MR,. Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer. Genes Chromosomes Cancer 2002; 33 (2): 201-205.